Detalles de la búsqueda
1.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Blood
; 137(1): 49-60, 2021 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32693406
2.
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Lancet Oncol
; 11(10): 934-41, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20739218
Resultados
1 -
2
de 2
1
Próxima >
>>